Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Dimitrios D Raptis, Christos S Mantzoros & Stergios A Polyzos. (2023) Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease. Therapeutics and Clinical Risk Management 19, pages 77-96.
Read now
Read now
Chara Tsiampali, Paraskevi Papaioannidou, Antonis Goulas & Stergios A. Polyzos. (2023) The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease. Expert Review of Clinical Pharmacology 16:11, pages 1063-1072.
Read now
Read now
Articles from other publishers (37)
Ilias D. Vachliotis & Stergios A. Polyzos. (2023) The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Current Obesity Reports.
Crossref
Crossref
Lara C. Lewis, Lingyan Chen, L. Shahul Hameed, Robert R. Kitchen, Cyrielle Maroteau, Shilpa R. Nagarajan, Jenny Norlin, Charlotte E. Daly, Iwona Szczerbinska, Sara Toftegaard Hjuler, Rahul Patel, Eilidh J. Livingstone, Tom N. Durrant, Elisabeth Wondimu, Soumik BasuRay, Anandhakumar Chandran, Wan-Hung Lee, Sile Hu, Barak Gilboa, Megan E. Grandi, Enrique M. Toledo, Abdullah H.A. Erikat, Leanne Hodson, William G. Haynes, Natalie W. Pursell, Ken Coppieters, Jan Fleckner, Joanna M.M. Howson, Birgitte Andersen & Maxwell A. Ruby. (2023) Hepatocyte mARC1 promotes fatty liver disease. JHEP Reports 5:5, pages 100693.
Crossref
Crossref
Emir Muzurović, Stergios A. Polyzos, Dimitri P. Mikhailidis, Sanja Borozan, Dušanka Novosel, Oleg Cmiljanić, Nataša Kadić & Christos S. Mantzoros. (2023) Non-alcoholic Fatty Liver Disease in Children. Current Vascular Pharmacology 21:1, pages 4-25.
Crossref
Crossref
Xiaoxin X. Wang, Cen Xie, Andrew E. Libby, Suman Ranjit, Jonathan Levi, Komuraiah Myakala, Kanchan Bhasin, Bryce A. Jones, David J. Orlicky, Shogo Takahashi, Alexander Dvornikov, David E. Kleiner, Stephen M. Hewitt, Luciano Adorini, Jeffrey B. Kopp, Kristopher W. Krausz, Avi Rosenberg, James L. McManaman, Charles E. Robertson, Diana Ir, Daniel N. Frank, Yuhuan Luo, Frank J. Gonzalez, Enrico Gratton & Moshe Levi. (2022) The role of FXR and TGR5 in reversing and preventing progression of Western diet–induced hepatic steatosis, inflammation, and fibrosis in mice. Journal of Biological Chemistry 298:11, pages 102530.
Crossref
Crossref
Evangelia S. Makri, Eleftheria Makri & Stergios A. Polyzos. (2022) Combination Therapies for Nonalcoholic Fatty Liver Disease. Journal of Personalized Medicine 12:7, pages 1166.
Crossref
Crossref
Apostolis Papaefthymiou, Spyros Potamianos, Antonis Goulas, Michael Doulberis, Jannis Kountouras & Stergios A Polyzos. (2022) Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. Journal of Crohn's and Colitis 16:5, pages 852-862.
Crossref
Crossref
Stergios A. Polyzos, Dimitrios G. Goulis, Olga Giouleme, Georgios S. Germanidis & Antonis Goulas. (2022) Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Current Obesity Reports 11:3, pages 166-179.
Crossref
Crossref
Stergios A. Polyzos, Konstantinos Xanthopoulos & Jannis Kountouras. (2022) Cilofexor for the Treatment of Nonalcoholic Steatohepatitis. Current Vascular Pharmacology 20:2, pages 111-113.
Crossref
Crossref
RehabF Abdel-Rahman. (2022) Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches. Asian Pacific Journal of Tropical Biomedicine 12:3, pages 99.
Crossref
Crossref
Irina V. Berezhnaya, Irina N. Zakharova, Mariia A. Simakova & Aleksandra I. Sgibneva. (2021) Polyunsaturated fatty acids: omega-3 and omega-6 and nonalcoholic fatty liver disease. Pediatrics. Consilium Medicum:4, pages 335-340.
Crossref
Crossref
Evangelia S. Makri, Antonis Goulas & Stergios A. Polyzos. (2021) Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. European Journal of Pharmacology 907, pages 174272.
Crossref
Crossref
Krishnan Suresh Babu & Deivanayagam Paradesi. (2020) Investigation of Related Impurities in Metadoxine by a Reversed Phase High Performance Liquid Chromatography Technique. Analytical Sciences 37:4, pages 581-584.
Crossref
Crossref
Yan Zhang, Bo Li, Nan Liu, Peixi Wang & Jinghua He. (2021) Evaluation of Different Anthropometric Indicators for Screening for Nonalcoholic Fatty Liver Disease in Elderly Individuals. International Journal of Endocrinology 2021, pages 1-12.
Crossref
Crossref
Evangelia Makri, Antonis Goulas & Stergios A. Polyzos. (2021) Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. Archives of Medical Research 52:1, pages 25-37.
Crossref
Crossref
Evangelia Makri, Marina Kita, Antonis Goulas, Paraskevi Papaioannidou, Zoe A. Efstathiadou, Fotini Adamidou & Stergios A. Polyzos. (2020) Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14:6, pages 1913-1919.
Crossref
Crossref
Stergios A. Polyzos & Christos S. Mantzoros. (2020) Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 111, pages 154318.
Crossref
Crossref
Stergios A. Polyzos, Eun Seok Kang, Chrysoula Boutari, Eun-Jung Rhee & Christos S. Mantzoros. (2020) Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 111, pages 154203.
Crossref
Crossref
Ke Pei, Ting Gui, Dongfang Kan, Huichao Feng, Yanqiang Jin, Ying Yang, Qian Zhang, Ziwei Du, Zhibo Gai, Jibiao Wu & Yunlun Li. (2020) An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. BioMed Research International 2020, pages 1-12.
Crossref
Crossref
Michael Doulberis, Kasiani Papadimitriou, Apostolis Papaefthymiou, Jannis Kountouras & Stergios A. Polyzos. (2020) The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. Exploration of Medicine 1:4, pages 170-183.
Crossref
Crossref
Stergios A. Polyzos, Jannis Kountouras & Christos S. Mantzoros. (2020) Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Metabolism 104, pages 154144.
Crossref
Crossref
Stergios A. Polyzos, Jannis Kountouras, Antonis Goulas & Leonidas Duntas. (2019) Selenium and selenoprotein P in nonalcoholic fatty liver disease. Hormones 19:1, pages 61-72.
Crossref
Crossref
Vasiliki Venetsanaki, Zacharoula Karabouta & Stergios A. Polyzos. (2019) Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology 863, pages 172661.
Crossref
Crossref
Vasiliki Venetsanaki & Stergios A. Polyzos. (2019) Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. Current Vascular Pharmacology 17:6, pages 546-555.
Crossref
Crossref
Stergios A. Polyzos, Jannis Kountouras & Christos S. Mantzoros. (2019) Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism 96, pages iii-v.
Crossref
Crossref
Stergios A. Polyzos, Nikolaos Perakakis & Christos S. Mantzoros. (2019) Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism 96, pages 66-82.
Crossref
Crossref
Stergios A. Polyzos & Jannis Kountouras. (2019)
Helicobacter pylori
infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy
. Helicobacter, pages e12588.
Crossref
Crossref
Stergios A. Polyzos, Jannis Kountouras & Christos S. Mantzoros. (2019) Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 92, pages 82-97.
Crossref
Crossref
Stergios A. Polyzos, Jannis Kountouras, Athanasios D. Anastasilakis, Polyzois Makras, Gerhard Hawa, Linda Sonnleitner, Albert Missbichler, Michael Doulberis, Panagiotis Katsinelos & Evangelos Terpos. (2018) Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones 17:4, pages 573-579.
Crossref
Crossref
Stergios A. Polyzos & Andrew N. Margioris. (2018) Sarcopenic obesity. Hormones 17:3, pages 321-331.
Crossref
Crossref
Stergios A. Polyzos, Jannis Kountouras, Sotiris Anastasiadis, Michael Doulberis & Panagiotis Katsinelos. (2018) Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes‐like approach?. Hepatology 68:1, pages 389-389.
Crossref
Crossref
Stergios A. Polyzos, Athanasios D. Anastasilakis, Zoe A. Efstathiadou, Polyzois Makras, Nikolaos Perakakis, Jannis Kountouras & Christos S. Mantzoros. (2017) Irisin in metabolic diseases. Endocrine 59:2, pages 260-274.
Crossref
Crossref
Juan-Fen Mo, Jia-Yuan Wu, Li Zheng, Ya-Wei Yu, Tian-Xin Zhang, Li Guo & Yi Bao. (2018)
Therapeutic efficacy of polydatin for nonalcoholic fatty liver disease
via
regulating inflammatory response in obese mice
. RSC Advances 8:54, pages 31194-31200.
Crossref
Crossref
Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros, Vaia Polymerou & Panagiotis Katsinelos. (2017)
Effects of combined low‐dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non‐invasive indices of steatosis and fibrosis, and adipokine levels in non‐alcoholic fatty liver disease:
a
randomized controlled trial
. Diabetes, Obesity and Metabolism 19:12, pages 1805-1809.
Crossref
Crossref
Michael Doulberis, Georgios Kotronis, Dimitra Gialamprinou, Jannis Kountouras & Panagiotis Katsinelos. (2017) Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 71, pages 182-197.
Crossref
Crossref
Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses S. Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S. Rallidis, Dimitrios Richter, Apostolos G. Tsapas, Alexandros D. Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis & Christos Mantzoros. (2017) The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 71, pages 17-32.
Crossref
Crossref
Mark Benedict & Xuchen Zhang. (2017) Non-alcoholic fatty liver disease: An expanded review. World Journal of Hepatology 9:16, pages 715.
Crossref
Crossref
Hongshan Li, Hao Ying, Airong Hu, Dezhou Li & Yaoren Hu. (2017) Salidroside Modulates Insulin Signaling in a Rat Model of Nonalcoholic Steatohepatitis. Evidence-Based Complementary and Alternative Medicine 2017, pages 1-6.
Crossref
Crossref